Transformation in Sight
Dedicated to preserving the sight of individuals impacted by retinal disease.
Breakthrough scientific advancement
Our unique therapeutic approach aims to prevent the accumulation of toxic vitamin A dimers in the retina, which are associated with Stargardt disease and geographic atrophy secondary to age-related macular degeneration.
Our oral investigational therapy is a new molecular entity designed to reduce vitamin A dimerization without modulating the visual cycle.
Explore our clinical trials
Our clinical studies are focused in Stargardt disease (TEASE studies) and geographic atrophy (SAGA study).
Sight is precious and every minute counts
Every day that goes by, patients with progressive degenerative retinal diseases are losing some of their sight. Every moment matters, and that is why we are working diligently to bring sight-preserving therapies to patients and address the highest unmet needs in retinal disease.
The urgent unmet need that drives us
Stargardt disease is a rare genetic condition that leads to severe vision loss in children and adults, and for which there is no approved treatment. We are working diligently to bring the first therapeutic option to this community.
Make a difference
We are looking for highly skilled and experienced individuals who share our sense of purpose and urgency to bring meaningful therapies to the patient communities we serve.
Up for the challenge?
